Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03340766 · ClinicalTrials.gov registry record · Phase 1
Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT03340766 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 31 participants.
The verdict
NCT03340766, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the maximum tolerated dose (MTD) of blinatumomab in combination with pembrolizumab in adults with relapsed or refractory (r/r) DLBCL.
Interventions
- DRUG Pembrolizumab
- DRUG Blinatumomab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2018-03-16 |
| Est. Completion | 2023-08-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03340766
The ClinicalTrials.gov registry entry for NCT03340766 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03340766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03340766 about?
NCT03340766 is a clinical study titled "Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)". The primary objective of the study is to determine the maximum tolerated dose (MTD) of blinatumomab in combination with pembrolizumab in adults with relapsed or refractory (r/r) DLBCL.
What is the current status of trial NCT03340766?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2018-03-16. Estimated completion is 2023-08-14.
What interventions are being tested in trial NCT03340766?
The interventions under investigation include: Pembrolizumab (DRUG), Blinatumomab (DRUG).
Who is sponsoring clinical trial NCT03340766?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.